Venlafaxine: A 2003 update

Clinical Therapeutics

Volumn 25, Issue 8, 2003, Pages 2138-2154

  Gutierrez, Mary A ^a,b   Stimmel, Glen L ^a,b   Aiso, Janet Y ^c  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c JANEN Clinical Pharmacy Consultants   (United States)

Author keywords

Antidepressant; Generalized anxiety disorder; Treatment remission; Treatment resistant depression; Venlafaxine; Venlafaxine XR

Indexed keywords

AMFEBUTAMONE; DULOXETINE; FLUOXETINE; FLUVOXAMINE; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; PAROXETINE; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

AGITATION; ANXIETY DISORDER; BEHAVIOR THERAPY; CHRONIC PAIN; CLINICAL TRIAL; CONGENITAL MALFORMATION; DEPRESSION; DOSE RESPONSE; DROWSINESS; DRUG EFFICACY; DRUG MARKETING; DRUG MECHANISM; DRUG OVERDOSE; DRUG RELEASE; DRUG SAFETY; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; GENERALIZED ANXIETY DISORDER; HISTORY OF MEDICINE; HUMAN; HYPOTENSION; LONG TERM CARE; META ANALYSIS; OBESITY; OBSESSIVE COMPULSIVE DISORDER; PSYCHOPHARMACOLOGY; PSYCHOPHARMACOTHERAPY; REMISSION; REVIEW; RISK ASSESSMENT; SEDATION; SEIZURE; SEROTONIN SYNDROME; SEROTONINERGIC TRANSMISSION; SEXUAL DYSFUNCTION; SIDE EFFECT; SUICIDAL BEHAVIOR; TERATOGENICITY; WITHDRAWAL SYNDROME;

EID: 0041885433     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(03)80210-2     Document Type: Article

References (75)

1. Stahl SM, Entsuah R, Rudolph RL. Comparative efficacy between venlafaxine and SSRIs: A pooled analysis of patients with depression. Biol Psychiatry. 2002;52:1166-1174.
2. Deakin B, Dursun S. Optimizing antidepressant treatment: Efficacy and tolerability. Int Clin Psychopharmacol. 2002;17(Suppl 1):S13-S24.
3. Ellingrod VL, Perry PJ. Venlafaxine: A heterocyclic antidepressant. Am J Hosp Pharm. 1994;51:3033-3046.
4. Augustin BG, Cold JA, Jann MW. Venlafaxine and nefazodone, two pharmacologically distinct antidepressants. Pharmacotherapy. 1997;17:511-530.
5. Rudolph RL, Derivan AT. The safety and tolerability of venlafaxine hydrochloride: Analysis of the clinical trials database. J Clin Psychopharmacol. 1996;16(Suppl 2):54S-61S.
6. Harvey AT, Rudolph RL, Preskorn SH. Evidence of the dual mechanisms of action of venlafaxine. Arch Gen Psychiatry. 2000;57:503-509.
7. Tran PV, Bymaster FP, McNamara RK, Potter WZ. Dual monoamine modulation for improved treatment of major depressive disorder. J Clin Psychopharmacol. 2003;23:78-86.
8. Demitrack MA. Can monoamine-based therapies be improved? J Clin Psychiatry. 2002;63(Suppl 2):14-18.
9. Feighner JP. Overview of antidepressants currently used to treat anxiety disorders. J Clin Psychiatry. 1999;60(Suppl 22):18-22.
10. Stahl SM. Selecting an antidepressant by using mechanism of action to enhance efficacy and avoid side effects. J Clin Psychiatry. 1998;59(Suppl 18):23-29.
11. Stimmel GL. Through the hourglass: Antidepressants and their mechanisms. Mental Health Econ. 2001;5:7-8.
12. Hirschfeld RM. Efficacy of SSRIs and newer antidepressants in severe depression: Comparison with TCAs. J Clin Psychiatry. 1999;60:326-335.
13. Parker G, Roy K, Wilhelm K, Mitchell P. Assessing the comparative effectiveness of antidepressant therapies: A prospective clinical practice study. J Clin Psychiatry. 2001;62:117-125.
14. Stimmel GL, McCombs JS, Aiso JY. Psychotropic drug use patterns: Reality versus ideal. Econ Neurosci. 2001;3:66-68.
15. Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry. 2001;178:234-241.
16. Nierenberg AA, Wright EC. Evolution of remission as the new standard in the treatment of depression. J Clin Psychiatry. 1999;60(Suppl 22):7-11.
17. Stahl SM. Why settle for silver, when you can go for gold? Response vs. recovery as the goal of antidepressant therapy. J Clin Psychiatry. 1999;60:213-214.
18. Paykel ES, Ramana R, Cooper Z, et al. Residual symptoms after partial remission: An important outcome in depression. Psychol Med. 1995;25:1171-1180.
19. Kelsey JE. Clinician perspective on achieving and maintaining remission in depression. J Clin Psychiatry. 2001;62(Suppl 26):16-21.
20. American Psychiatric Association. Practice guidelines for the treatment of patients with major depressive disorder (revision). Am J Psychiatry. 2000;157(Suppl):1-45.
21. Scott J, Teasdale JD, Paykel ES, et al. Effects of cognitive therapy on psychological symptoms and social functioning in residual depression. Br J Psychiatry. 2000;177:440-446.
22. Thase ME, Howland RH, Friedman ES. Treating antidepressant nonresponders with augmentation strategies: An overview. J Clin Psychiatry. 1998;59(Suppl 5):5-12.
23. Entsuah AR, Huang H, Thase ME. Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo. J Clin Psychiatry. 2001;62:869-877.
24. Einarson TR, Ankian SR, Casciano J, Doyle JJ. Comparison of extended-release venlafaxine, selective serotonin reuptake inhibitors, and tricyclic antidepressants in the treatment of depression: A meta-analysis of randomized controlled trials. Clin Ther. 1999;21:296-308.
25. Smith D, Dempster C, Glanville J, et al. Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: A meta-analysis. Br J Psychiatry. 2002;180:396-404.
26. Mehtonen OR Sogaard J, Roponen P, Behnke K, for the Venlafaxine 631 Study Group. Randomized, double-blind comparison of venlafaxine and sertraline in outpatients with major depressive disorder. J Clin Psychiatry. 2000;61:95-100.
27. Guelfi JD, Ansseau M, Timmerman L, Korsgaard S, for the Mirtazapine-Venlafaxine Study Group. Mirtazapine versus venlafaxine in hospitalized severely depressed patients with melancholic features. J Clin Psychopharmacol. 2001;21:425-431.
28. Freemantle N, Anderson IM, Young P. Predictive value of pharmacological activity for the relative efficacy of antidepressant drugs. Meta-regression analysis. Br J Psychiatry. 2000;177:292-302.
29. Nierenberg AA. Do some antidepressants work faster than others? J Clin Psychiatry. 2001;62(Suppl 15):22-25.
30. Stahl SM, Nierenberg AA, Gorman JM. Evidence of early onset of antidepressant effect in randomized controlled trials. J Clin Psychiatry. 2001;62(Suppl 4):17-23.
31. Blier P. Possible neurobiological mechanisms underlying faster onset of antidepressant action. J Clin Psychiatry. 2001;62(Suppl 4):7-11.
32. Sackeim HA. The definition and meaning of treatment-resistant depression. J Clin Psychiatry. 2001;62(Suppl 16):10-17.
33. O'Reardon JP, Amsterdam JD. Overview of treatment-resistant depression and its management. In: Amsterdam JD, Hornig M, Nierenberg AA, eds. Treatment-Resistant Mood Disorders. Cambridge, UK: Cambridge University Press; 2001:30-45.
34. Souery D, Lipp O, Massat I. The characterization and definition of treatment-resistant mood disorders. In: Amsterdam JD, Hornig M, Nierenberg AA, eds. Treatment-Resistant Mood Disorders. Cambridge, UK: Cambridge University Press; 2001:3-29.
35. de Montigny C, Silverstone PH, Debonnel G, et al. Venlafaxine in treatment-resistant major depression: A Canadian multicenter, open-label trial. J Clin Psychopharmacol. 1999;19:401-406.
36. Mitchell PB, Schweitzer I, Burrows G, et al. Efficacy of venlafaxine and predictors of response in a prospective open-label study of patients with treatment-resistant major depression. J Clin Psychopharmacol. 2000;20:483-487.
37. Schweitzer I, Burrows G, Tuckwell V, et al. Sustained response to open-label venlafaxine in drug-resistant major depression. J Clin Psychopharmacol. 2001;21:185-189.
38. Saiz-Ruiz J, Ibanez A, Diaz-Marsa M, et al. Efficacy of venlafaxine in major depression resistant to selective serotonin reuptake inhibitors. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26:1129-1134.
39. Kaplan EM. Efficacy of venlafaxine in patients with major depressive disorder who have unsustained or no response to selective serotonin reuptake inhibitors: An open-label, uncontrolled study. Clin Ther. 2002;24:1194-1200.
40. Poirier MF, Boyer P. Venlafaxine and paroxetine in treatment-resistant depression. Double-blind, randomised comparison. Br J Psychiatry. 1999;175:12-16.
41. Fava M. New approaches to the treatment of refractory depression. J Clin Psychiatry. 2000;61(Suppl 1):26-32.
42. Davidson JR. Pharmacotherapy of generalized anxiety disorder. J Clin Psychiatry. 2001;62(Suppl 11):46-50.
43. Sramek JJ, Zarotsky V, Cutler NR. Generalised anxiety disorder: Treatment options. Drugs. 2002;62:1635-1648.
44. Lydiard RB. An overview of generalized anxiety disorder: Disease state-appropriate therapy. Clin Ther. 2000;22(Suppl A):A3-A24.
45. Nutt DJ. Neurobiological mechanisms in generalized anxiety disorder. J Clin Psychiatry. 2001;62(Suppl 11):22-27.
46. Ballenger JC. Overview of different pharmacotherapies for attaining remission in generalized anxiety disorder. J Clin Psychiatry. 2001;62(Suppl 19):11-19.
47. Bandelow B, Zohar J, Hollander E, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders. World J Biol Psychiatry. 2002;3:171-199.
48. Hackett D. Venlafaxine XR in the treatment of anxiety. Acta Psychiatr Scand Suppl. 2000;406:30-35.
49. Gorman JM. Treating generalized anxiety disorder. J Clin Psychiatry. 2003;64(Suppl 2):24-29.
50. Meoni P, Salinas E, Brault Y, Hackett D. Pattern of symptom improvement following treatment with venlafaxine XR in patients with generalized anxiety disorder. J Clin Psychiatry. 2001;62:888-893.
51. Rickels K, Pollack MH, Sheehan DV, Haskins JT. Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder. Am J Psychiatry. 2000;157:968-974.
52. Gelenberg AJ, Lydiard RB, Rudolph RL, et al. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial. JAMA. 2000;283:3082-3088.
53. Allgulander C, Hackett D, Salinas E. Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: Twenty-four-week placebo-controlled dose-ranging study. Br J Psychiatry. 2001;179:15-22.
54. Katz IR, Reynolds CF III, Alexopoulos GS, Hackett D. Venlafaxine ER as a treatment for generalized anxiety disorder in older adults: Pooled analysis of five randomized placebo-controlled clinical trials. J Am Geriatr Soc. 2002;50:18-25.
55. Montgomery SA, Sheehan DV, Meoni P, et al. Characterization of the longitudinal course of improvement in generalized anxiety disorder during long-term treatment with venlafaxine XR. J Psychiatr Res. 2002;36:209-217.
56. Sheehan DV. Attaining remission in generalized anxiety disorder: Venlafaxine extended release comparative data. J Clin Psychiatry. 2001;62(Suppl 19):26-31.
57. Greist JH, Jefferson JW, Kobak KA, et al. Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. A meta-analysis. Arch Gen Psychiatry. 1995;52:53-60.
58. Yaryura-Tobias JA, Neziroglu FA. Venlafaxine in obsessive-compulsive disorder. Arch Gen Psychiatry. 1996;53:653-654. Letter.
59. Albert U, Aguglia E, Maina G, Bogetto F. Venlafaxine versus clomipramine in the treatment of obsessive-compulsive disorder: A preliminary single-blind, 12-week, controlled study. J Clin Psychiatry. 2002;63:1004-1009.
60. Sumpton JE, Moulin DE. Treatment of neuropathic pain with venlafaxine. Ann Pharmacother. 2001;35:557-559.
61. Max MB, Lynch SA, Muir J, et al. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med. 1992;326:1250-1256.
62. Enggaard TP, Klitgaard NA, Gram LF, et al. Specific effect of venlafaxine on single and repetitive experimental painful stimuli in humans. Clin Pharmacol Ther. 2001;69:245-251.
63. Songer DA, Schulte H. Venlafaxine for the treatment of chronic pain. Am J Psychiatry. 1996;153:737. Letter.
64. Perry NK. Venlafaxine-induced serotonin syndrome with relapse following amitriptyline. Postgrad Med J. 2000;76:254-256.
65. Bhatara VS, Magnus RD, Paul KL, Preskorn SH. Serotonin syndrome induced by venlafaxine and fluoxetine: A case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms. Ann Pharmacother. 1998;32:432-436.
66. Diamond S, Pepper BJ, Diamond ML, et al. Serotonin syndrome induced by transitioning from phenelzine to venlafaxine: Four patient reports. Neurology. 1998;51:274-276.
67. Pan JJ, Shen WW. Serotonin syndrome induced by low-dose venlafaxine. Ann Pharmacother. 2003;37:209-211.
68. Haddad PM. Antidepressant discontinuation syndromes. Drug Saf. 2001;24:183-197.
69. Fava M, Mulroy R, Alpert J, et al. Emergence of adverse events following discontinuation of treatment with extended-release venlafaxine. Am J Psychiatry. 1997;154:1760-1762.
70. Einarson A, Fatoye B, Sarkar M, et al. Pregnancy outcome following gestational exposure to venlafaxine: A multicenter prospective controlled study. Am J Psychiatry. 2001;158:1728-1730.
71. Effexor XR [package insert]. Philadelphia, Pa: Wyeth Pharmaceuticals; 2003.
72. Pisani F, Oteri G, Costa C, et al. Effects of psychotropic drugs on seizure threshold. Drug Saf. 2002;25:91-110.
73. Schlienger RG, Klink MH, Eggenberger C, Drewe J. Seizures associated with therapeutic doses of venlafaxine and trimipramine. Ann Pharmacother 2000;34:1402-1405.
74. Sarko J. Antidepressants, old and new. A review of their adverse effects and toxicity in overdose. Emerg Med Clin North Am. 2000;18:637-654.
75. Buckley NA, McManus PR. Fatal toxicity of serotoninergic and other antidepressant drugs: Analysis of United Kingdom mortality data. BMJ. 2002;325:1332-1333.